New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 25, 2012
05:55 EDTAON, AON, GT, GT, COL, COL, NWL, NWL, MCO, MCO, LYB, LYB, MRK, MRK, LM, LM, IPG, IPG, CVH, CVH, CMCSA, CMCSA, WY, WYCompanies reporting Before the Market Open on Friday, October 26
Notable companies reporting before the opening bell include Aon (AON), Comcast (CMCSA), Coventry Health Care (CVH), Interpublic Group of Companies (IPG), Legg Mason (LM), Merck & Co (MRK), LyondellBasell Industries (LYB), Moodys (MCO), Newell Rubbermaid (NWL), Rockwell Collins (COL), The Goodyear Tire & Rubber (GT) and Weyerhaeuser (WY).
News For AON;CMCSA;CVH;IPG;LM;MRK;LYB;MCO;NWL;COL;GT;WY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 2, 2015
07:30 EDTMCOMoody's to hold a webinar
Subscribe for More Information
July 1, 2015
08:40 EDTCMCSABofA/Merrill's Top 10 US Ideas for Q3
BofA/Merrill published its Top 10 U.S. Ideas Quarterly for Q3 that identifies companies it sees having significant catalysts in the next three months. The list includes eight Buys and two Underperforms. The Buys are Applied Materials (AMAT), Boise Cascade (BCC), Burlington Stores (BURL), Comcast (CMCSA), Comerica (CMA), Eli Lilly (LLY), Facebook (FB), and International Game (IGT). The Underperforms are BlackBerry (BBRY) and PBF Energy (PBF).
07:25 EDTNWLConsumer goods makers challenged by surging freight costs, WSJ reports
Subscribe for More Information
07:04 EDTCVHCoventry Health says Jarrod Pntius begins role as general counsel, CAO
Subscribe for More Information
07:03 EDTCMCSAComcast attractive during market uncertainty, say Brean Capital
Subscribe for More Information
June 30, 2015
07:15 EDTCMCSAExecutives' Club of Chicago to hold a discussion
Subscribe for More Information
June 29, 2015
14:11 EDTCMCSANBCUniversal ending relationship with Donald Trump, LA Times reports
Subscribe for More Information
08:39 EDTMRKMerck says Phase 3 Emend data shows it provides 'greater protection' from nausea
Merck announced results from a Phase 3 study investigating the safety and efficacy of single-dose Emend for Injection, Merck’s substance P/neurokinin receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting, or CINV, in adult cancer patients receiving moderately emetogenic chemotherapy, or MEC. In the study, the first to evaluate an intravenous NK-1 receptor antagonist for the prevention of CINV associated with MEC, the single-dose Emend for Injection regimen provided greater protection from nausea and vomiting following administration of chemotherapy versus an active control of placebo with other anti-vomiting medicines. These data were presented in an oral session at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on “Supportive Care in Cancer” in Copenhagen.
June 28, 2015
15:40 EDTCMCSAUniversal's 'Jurassic World' leads U.S. weekend box office with $54.2M
For the weekend of June 28, Comcast (CMCSA, CMCSK) subsidiary Universal's "Jurassic World" topped domestic box office charts at $54.2M. Disney's (DIS) "Inside Out" landed in second place with $52.1M, while Universal's "Ted 2" came in third with $32.9M. Time Warner (TWX) subsidiary Warner Bros.' "Max" and Fox's (FOX, FOXA) "Spy" took fourth and fifth place at $12.2M and $7.8M, respectively. Data gathered by Rentrak.
13:13 EDTLMLegg Mason shares may return 20% or more in one year, Barron's says
Subscribe for More Information
June 25, 2015
09:08 EDTGTGoodyear Tire to close Wolverhampton, U.K., facility, cut 360-390 positions
The Goodyear Tire & Rubber Company said in a regulatory filing that on June 23, it approved rationalization plans in its Europe, Middle East and Africa strategic business unit in order to strengthen the company’s global competiveness. The rationalization plans include closing the Wolverhampton, United Kingdom mixing and retreading facility and transferring its production to existing manufacturing facilities across EMEA. The plans also include the transfer of consumer tire production from the manufacturing facility in Wittlich, Germany to existing manufacturing facilities in EMEA. These plans, which will result in a net reduction of approximately 360 to 390 associate positions, remain subject to consultation with relevant employee representative bodies.The company expects to be substantially complete with these rationalization plans by the end of 2016 and estimates total charges associated with these actions to be between $70M-$80M, or $60M-$70M after taxes and minority interest, of which $55M-$60M is expected to be cash charges primarily related to severance payments and contractual obligations and approximately $15M-$20M is expected to be non-cash charges primarily related to accelerated depreciation and other asset related charges. The company expects to record approximately $30M of charges in the second quarter of 2015 associated with these plans. Charges of approximately $10M are expected to be recognized in the second half of 2015.Once completed, these actions are expected to improve EMEA segment operating income by approximately $30M annually, beginning in 2017.
June 24, 2015
19:53 EDTCMCSAComcast to offer EA games over cable box, DSLReports says
Subscribe for More Information
13:58 EDTCMCSAChernin, NBCUniversal agree on two year deal, L.A. Times reports
Subscribe for More Information
09:07 EDTMRKCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
08:25 EDTCMCSANetflix on pace to have larger audience than all networks, FBR says
FBR Capital analyst Barton Crockett says that while Netflix (NFLX) is not rated by Nielsen (NLSN), the 10B hours streamed in Q1 reported by the company are equivalent to having a 24-hour rating of 2.6, on par with Disney's (DIS) ABC and Comcast's (CMCSA) NBC. And while ratings at broadcasters are falling on average, Netflix is growing its ratings at a 40%-plus compound annual rate, Crockett tells investors this morning in a research note. At this pace, Netflix in a year will have a larger 24-hour audience than all broadcast networks, he contends. Regarding last night's 7-for-1 stock split announcement, Crockett says the move reflects management's confidence in the "durability of the recent stock surge." For perspective, three years ago Netflix shares were around $60. This morning they are trading up $18.69 to $699.88 in the pre-market. Crockett has an Outperform rating on the streaming service with a $900 price target.
07:16 EDTLYBCredit Suisse to hold a conference
Subscribe for More Information
June 23, 2015
13:09 EDTCMCSAHulu to sell Showtime premium package for subscribers
Hulu (DIS;NWSA;CMSA) will sell Showtime Networks' (CBS) Internet streaming service to subscribers in early July, reports Variety. Hulu will offer Showtime to its subscribers for $8.99 in addition to the $7.99 fee Hulu subscribers pay per month.Reference Link
12:52 EDTNWLStamps.com receives second request from DOJ for information in PSI acquisition
Subscribe for More Information
June 22, 2015
15:04 EDTCMCSAT-Mobile could abandon DISH for Comcast, Forbes contributor says
Subscribe for More Information
06:59 EDTCMCSAComcast, NBCUniversal using cross-promotional strategy, NY Times says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use